Literature DB >> 16166096

Altered exon usage in the juxtamembrane domain of mouse and human RON regulates receptor activity and signaling specificity.

Xin Wei1, Li Hao, Shuang Ni, Qingping Liu, Jie Xu, Pamela H Correll.   

Abstract

Alternative splicing of signaling proteins can contribute to the complexity of signaling networks. We find that expression of mouse RON, but not human RON, results in constitutive receptor autophosphorylation, ligand-independent activation of the mitogen-activated protein kinase pathway, and association of the receptor with c-Src. Using chimeric receptors, we mapped the region for this difference in signaling capacity of mouse and human RON to the juxtamembrane domain. Expression of these receptors in primary erythroid progenitor cells also demonstrated a functional difference in the ability of mouse and human RON to support erythropoietin-independent colony formation that mapped to the juxtamembrane domain. Splicing of the mouse RON receptor tyrosine kinase transcript results in the constitutive deletion of an exon used by all other known RON orthologs that encodes part of the juxtamembrane domain of the receptor. Mutational analysis indicated that the two tyrosines present in this region in human RON, one of which has been previously shown to be a c-Cbl binding site, are not responsible for this difference. However, deletion of this region in the context of human RON enhanced receptor phosphorylation, activation of mitogen-activated protein kinase, and association of c-Src at levels comparable with those observed with mouse RON. These data provide direct evidence that the divergence of exon usage among different species can generate a protein with novel activity and subsequently add to the complexity of cellular signaling regulation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16166096     DOI: 10.1074/jbc.M506806200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

1.  Inhibition of TLR4-induced IκB kinase activity by the RON receptor tyrosine kinase and its ligand, macrophage-stimulating protein.

Authors:  Manujendra Ray; Shan Yu; Daniel R Sharda; Caleph B Wilson; QingPing Liu; Naveen Kaushal; K Sandeep Prabhu; Pamela A Hankey
Journal:  J Immunol       Date:  2010-11-15       Impact factor: 5.422

2.  Regulation of macrophage arginase expression and tumor growth by the Ron receptor tyrosine kinase.

Authors:  Daniel R Sharda; Shan Yu; Manujendra Ray; Mario Leonardo Squadrito; Michele De Palma; Thomas A Wynn; Sidney M Morris; Pamela A Hankey
Journal:  J Immunol       Date:  2011-08-01       Impact factor: 5.422

Review 3.  Function of alternative splicing.

Authors:  Olga Kelemen; Paolo Convertini; Zhaiyi Zhang; Yuan Wen; Manli Shen; Marina Falaleeva; Stefan Stamm
Journal:  Gene       Date:  2012-08-15       Impact factor: 3.688

Review 4.  MSP-RON signalling in cancer: pathogenesis and therapeutic potential.

Authors:  Hang-Ping Yao; Yong-Qing Zhou; Ruiwen Zhang; Ming-Hai Wang
Journal:  Nat Rev Cancer       Date:  2013-07       Impact factor: 60.716

5.  A truncated human NKG2D splice isoform negatively regulates NKG2D-mediated function.

Authors:  Cynthia L Baldwin; Taku Kambayashi; Mobin A Karimi; Oscar Aguilar; Baixiang Zou; Michael H Bachmann; James R Carlyle
Journal:  J Immunol       Date:  2014-08-04       Impact factor: 5.422

Review 6.  Met-related receptor tyrosine kinase Ron in tumor growth and metastasis.

Authors:  Purnima K Wagh; Belinda E Peace; Susan E Waltz
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

Review 7.  Ron receptor tyrosine kinase signaling as a therapeutic target.

Authors:  Nancy M Benight; Susan E Waltz
Journal:  Expert Opin Ther Targets       Date:  2012-07-26       Impact factor: 6.902

8.  HIV-1 Tat mediates degradation of RON receptor tyrosine kinase, a regulator of inflammation.

Authors:  Parisa Kalantari; Omid F Harandi; Pamela A Hankey; Andrew J Henderson
Journal:  J Immunol       Date:  2008-07-15       Impact factor: 5.422

9.  Significance of the entire C-terminus in biological activities mediated by the RON receptor tyrosine kinase and its oncogenic variant RON160.

Authors:  Yi Lu; Hang-Ping Yao; Ming-Hai Wang
Journal:  J Exp Clin Cancer Res       Date:  2008-10-25

Review 10.  Pathogenesis of RON receptor tyrosine kinase in cancer cells: activation mechanism, functional crosstalk, and signaling addiction.

Authors:  Ming-Hai Wang; Ruiwen Zhang; Yong-Qing Zhou; Hang-Ping Yao
Journal:  J Biomed Res       Date:  2013-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.